Poseida Therapeutics Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma May 13, 2019
Read More
NexImmune, Inc. Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials Partnership yields the first investment from newly launched MMRF…
Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals April 22, 2019
Poseida Therapeutics Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round April 22, 2019
3DBio Therapeutics 3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors April 1, 2019
AsclepiX Therapeutics AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease…
AsclepiX Therapeutics AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina AXT107 exhibited a dual…
Poseida Therapeutics, Inc. Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T…
Sightly Enterprises, Inc. Sightly and Horizon Media Score Over 99% in IAS YouTube Brand Safety Measurement Beta January 14, 2019
Poseida Therapeutics, Inc. Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T January 6, 2019